The new center will design novel drug-like molecules using generative AI and optimize existing compounds to enhance their ...

For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target, permanently blocking it. Transcription factors ...

Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review; Kura ...

BenevolentAI has entered a two-year agreement with the MRC Technology to investigate new small molecule and ... BPM 31510 – a drug now being investigated in several cancer indications, including ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics ... including cancer, metabolic disorders, and neurodegenerative ...

Photo credit: Mount Sinai Health System AI Small Molecule Drug Discovery Center Photo 2 ... for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative ...

Ethan Grimes, BS, and Paul Morgan, MD, conduct rational drug design at the newly launched AI Small Molecule Drug Discovery ... including cancer, metabolic disorders, and neurodegenerative diseases.